Children receive busulfan orally as part of myeloablative therapy before bone marrow transplantation for malignant and nonmalignant conditions. Children have been reported to have a low incidence of severe toxicity and significant rates of failure to achieve full engraftment. We evaluated the disposition of busulfan in children between 2 months and 3.6 years of age with lysosomal storage diseases, leukemia, and immunodeficiency disorders receiving oral doses of 1 or 2 mg/kg using a gas chromatographic assay. Peak concentrations were lower than those previously reported for adults, ranging from 1.4 to 5.2 pmol/L. The harmonic mean of the elimination half-life was 92 minutes, which is only slightly faster than that for adults (140 minutes). However, the area under the curve ranged from 400 to 1 ,OW (71 5 f 240) pmol -min/L. substantially lower USULFAN (MYLERAN, Burroughs-Wellcome Co,
B Research Triangle Park, NC; 1 ,Chis [methanesulfonyloxy] butane) is widely used as part of myeloablative chemotherapy for bone marrow transplantation for both malignant and nonmalignant conditions.'.' The busulfan dose of 1 mg/kg every 6 hours for 16 doses was established in phase I trials in adults in combination with cyclophosphamide* and subsequently reconfirmed for busulfan alone.' In these trials the dose-limiting toxicities for busulfan were mucositis and hepatic veno-occlusive disease.'." ' In children, minimal toxicity directly attributable to busulfan has been reported in most ~e r i e s ,~.~. "~'~ and some institutions have reported higher rates of failure to achieve full engraftment in ~h i l d r e n .~. '~. '~ Because it seemed possible that differences in drug disposition in children resulting in decreased drug exposure might result in both decreased toxicity and decreased efficacy, we proposed to evaluate drug disposition in children receiving busulfan as part of a preparative regimen for bone marrow transplantation. After modifying our original assay to make it feasible to measure busulfan concentrations using small blood samples,I5 we measured busulfan concentrations in young children with a variety of malignant and nonmalignant diseases.
METHODS
Plasma samples were obtained from 21 patients between 2 months and 5 years of age undergoing bone marrow transplantation between August, 1986, and December, 1988. Parents of all patients provided informed consent for participation in this protocol and in the transplantation protocol, which were approved by the institutional review board of the University of Minnesota Medical School, Minneapolis, MN, in accord with institutional, state, and federal guidelines. Busulfan was given either by mouth (as pulverized tablets in applesauce) or by nasogastric tube. Seven patients with Hurler syndrome, one patient with Niemann-Pick disease, and one patient with Krabbe disease received busulfan 1 mg/kg every 6 hours for eight doses, followed by 1.25 mg/kg for eight additional doses. Five patients with acute nonlymphocytic leukemia and one with aplastic anemia received 1 mg/kg every 6 hours for 16 doses as conditioning for a second transplant. Five patients with immunodeficiency disorders (two with WiskottAldrich syndrome, two with severe combined immunodeficiency, one with viral-associated hemophagocytic syndrome) and one patient with chronic myelocytic leukemia received 2 mg/kg every 12 hours for eight doses.
Busulfan concentrations in plasma were measured using a previously described gas chromatographic assay.''
Heparinized whole blood samples (3 cc) were obtained from indwelling venous catheters before busulfan and at 30, 60, 90, 120, 180, and 360 minutes after the first dose of busulfan. Seven patients had additional samples obtained on the same schedule after one subsequent dose (one patient after his fourth dose of 2 mg/kg, one after his eighth dose of 2 mg/kg, one after his 12th dose of 1 mg/kg, and four after their 16th dose of 1 mg/kg). Plasma was separated, frozen at -2OoC, and shipped frozen to Baltimore, MD, for assay between 1 week and 6 months after treatment.
Individual disposition curves were visually evaluated for suitable nonlinear models. An inadequate number of samples (54) was obtained for three patients; one patient had drug concentrations less than the sensitivity of the assay (0.1 jimol/L); and three patients had concentrations measured that had no apparent pattern with respect to time and were not further analyzed. Fourteen patients had data that were adequately fit by a onecompartment model with first order absorption and elimination.16 Parameter estimation using nonlinear least squares analysis was performed using PCNONLIN (Statistical Consultants, Lexington, loo%), and the absorption lag time. Area under the curve (AUC) contributed by a single dose of busulfan, absorption and elimination half-lives, and total body clearance rate were calculated using the parametric estimates.
Adult patients. We have previously reported the disposition of busulfan in patients receiving oral doses of 1 mg/kg as part of a preparative regimen for allogeneic or autologous bone marrow transplantation as treatment for acute myelogenous leukemic, lymphoma, acute lymphocytic leukemia, chronic myelogenous leukemia, and aplastic anemia." As previously described, blood samples were obtained at 20, 40, 60, 75, 90, 105, 120, 240, 241, 359, and 360 minutes after the first dose of busulfan, concentrations were determined by high-pressure liquid chromatography (HPLC), and the data fit to a one-compartment model with first order absorption and elimination using PCNONLIN. Of the 28 patients previously described, 25 were 2 1 6 years old, and their pharmacokinetic parameters have been compared with the 14 young children evaluated in this study, using a two-tailed Student's t-test for independent variables (CSS; Statsoft, Tulsa, OK).
RESULTS
Disposition curves were adequately described by a onecompartment pharmacokinetic model with first order absorption and elimination for 14 children between 2 months and 3.6 years of age. Typical elimination curves after the first busulfan dose are presented in Fig 1. There was considerable variability in individuals' patterns of absorption and elimination, with peak concentrations ranging from 1.4 to 5.2 pmol/L for patients receiving 1 mg/kg, and from 2 to 4.8 pmol/L for patients receiving 2 mg/kg. Table 1 presents the absorption and elimination constants, volumes of distribution (assuming complete bioavailability), and lag times estimated from drug concentrations obtained after the first dose of busulfan, as well as the calculated clearance rates. The elimination half-life ranged from 38 to 260 minutes, with a harmonic mean of 92 minutes. The AUC ranged from 400 to 983 pmol min/L in patients receiving 1 mg/kg, and from 401 to 998 pmol -min/L in patients receiving 2 mg/kg.
In the previously published study of 25 patients 216 years old," the elimination half-life ranged from 58 to 433 minutes, with a harmonic mean of 139 minutes. The AUC ranged from 710 to 5,140 pmol/min/L. Table 2 
In addition to intrapatient variability in the disposition of busulfan, there may be variability for a single patient receiving multiple doses. Seven children had plasma samples obtained after two busulfan doses. Four of these children had minimal differences in parameter estimates for the two doses. Two children had changes in elimination half-life: one increased from 60 minutes after the first dose to 95 minutes after the fourth dose; the other had a decrease in half-life from 230 minutes to 80 minutes. One child had a very large change in apparent volume of distribution, from 1.34 L/kg to 5.9 L/kg after the sixteenth dose.
DISCUSSION
Children between 2 months and 5 years of age with a variety of neoplastic and non-neoplastic diseases demonstrated differences in busulfan disposition compared with adults previously studied.".'* Clearance rate normalized to body surface area in these children appears to be 2.2-fold that in adults. There is also a 2.4-fold difference in the apparent volume of distribution, and less difference in the elimination rate constant K. Without parenteral drug, the bioavailability and the actual volume of distribution cannot be assessed. The fact that most of the difference in clearance rate between adults and small children appears as a difference in V suggests that drug absorption and/or first-pass elimination of busulfan may differ substantially in young children compared with adults. Three of seven children studied after two busulfan doses had significant alterations in apparent clearance rate (one increased and one decreased) and in apparent volume of distribution (one increased) in subsequent doses compared with the first dose. Ehrrson et all8 reported a significant change in K and V in one of five patients receiving multiple doses of 2 to 6 mg of busulfan, and a significant change in the apparent volumen of distribution in another patient. Trough levels measured by Hassan et all9 after each of 16 doses of 1 mg/kg were reproducible. In six adults receiving high doses of b u s~l f a n , '~ minor differences in kinetic parameters were found between the first and fifth3 or sixteenth3 doses. The true frequency of intrapatient variability is unknown; we are assessing this further in a randomized trial of dose adjustment based on therapeutic monitoring.
There are a variety of ways in which drug handling in young children may differ from adults.20-22 Altered drug absorption might be due to differences in drug administration (crushed tablets in applesauce versus tablets enclosed in gelatin capsules). Children have higher gastric pH and For personal use only. on October 22, 2017. by guest www.bloodjournal.org From associated toxicities may be multifactorial, the results of this study suggest that the decreased toxicity reported may be due to underdosing children based on busulfan regimens established in adults.
Several authors have expressed concern about engraftment failures in children who have received busulfan (8 to 16 mg/kg) and cytoxan as a preparative regimen.314.'2.'3 Hobbs et all3 reported that they changed their regimen to 80 mg/m2/d x 4, with a minimum dose of 16 mg/kg and a maximum dose of 20 mg/kg. Lucarelli et allz found that 5 of 24 children with @-thalassemia failed to engraft after treatment with 14 mg/kg, but only 1 of 16 treated a t 16 mg/kg failed to engraft.
The results presented here suggest that achieving busulfan exposure in children equivalent to adults may require doses 50% to 100% greater on a weight basis. Providing pediatric doses on the basis of surface area20,22*29 will more closely approximate adult exposures, but clearance rate normalized to body surface area in the children studied was still twice the clearance rate in adults. Since recurrent leukemia remains a significant problem for patients undergoing bone marrow tran~plantation,~~ achieving increased drug exposure may provide better antileukemic effect. In addition, higher doses may enhance the likelihood of donor engraftment. Since no pediatric phase I study has been done, we are performing a dose escalation study for busulfan in pediatric patients with pharmacokinetic monitoring. Additional information will be needed to provide dosing recommendations for older children and adolescents.
